Dolutegravir-selected HIV-1 containing the N155H and R263K resistance substitutions does not acquire additional compensatory mutations under drug pressure that lead to higher-level resistance and increased replicative capacity

Journal of Virology

Volumn 89, Issue 20, 2015, Pages 10482-10488

  Anstett, Kaitlin ^a,b   Fusco, Robert ^b   Cutillas, Vincent ^a,b   Mesplède, Thibault ^b   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; BIOCHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME SUBSTRATE COMPLEX; GENE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; INFECTION SENSITIVITY; N155H GENE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; R263K GENE; TISSUE CULTURE; VIRUS INFECTIVITY; VIRUS REPLICATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; MUTATION; REPRODUCTIVE FITNESS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; GENETIC FITNESS; HEK293 CELLS; HELA CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; QUINOLONES; RALTEGRAVIR POTASSIUM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84942163391     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01725-15     Document Type: Article

References (30)

1. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. 2008. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5:114. http://dx.doi.org/10.1186/1742-4690-5-114.
2. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203:1204-1214. http://dx.doi.org/10.1093/infdis/jir025.
3. Mesplede T, Quashie PK, Wainberg MA. 2012. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 7:401-408. http://dx.doi.org/10.1097/COH.0b013e328356db89.
4. Mesplede T, Quashie PK, Zanichelli V, Wainberg MA. 2014. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med 46:123-129. http://dx.doi.org/10.3109/07853890.2014.883169.
5. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a nextgeneration HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
6. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. http://dx.doi.org/10.1186/1742-4690-10-22.
7. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
8. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
9. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
10. Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg MA. 2015. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol 89:4681-4684. http://dx.doi.org/10.1128/JVI.03485-14.
11. Hurt CB, Sebastian J, Hicks CB, Eron JJ. 2014. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58:423-431. http://dx.doi.org/10.1093/cid/cit697.
12. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
13. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51-S58. http://dx.doi.org/10.1086/505356.
14. Hu X, Kuritzkes DR. 2010. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 55:148-155. http://dx.doi.org/10.1097/QAI.0b013e3181e9a87a.
15. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. 2013. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 57: 2654-2663. http://dx.doi.org/10.1128/AAC.02568-12.
16. Malet I, Soulie C, Tchertanov L, Derache A, Amellal B, Traore O, Simon A, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. 2008. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 80:754-761. http://dx.doi.org/10.1002/jmv.21169.
17. Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C. 2015. Nonvirological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. J Antimicrob Chemother 70:1921-1923.
18. Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, Nakahara K, Kobayashi M, Underwood MR, Sato A, Fujiwara T, Yoshinaga T. 2015. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother 59:2596-2606. http://dx.doi.org/10.1128/AAC.04844-14.
19. Quashie PK, Mesplede T, Wainberg MA. 2013. HIV drug resistance and the advent of integrase inhibitors. Curr Infect Dis Rep 15:85-100. http://dx.doi.org/10.1007/s11908-012-0305-1.
20. Ghosn J, Mazet AA, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy JF, Chaix ML. 2009. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother 64:433-434. http://dx.doi.org/10.1093/jac/dkp182.
21. Lataillade M, Chiarella J, Kozal MJ. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12:563-570.
22. Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. 2014. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother http://dx.doi.org/10.1093/jac/dku199.
23. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
24. Vavro C, Palumbo P, Wiznia A, Alvero C, Graham B, Fenton T, Hazra R, Townley E, Buchanan A, Horton J, Viani R, P1093 Study Group. 2015. Evolution of HIV-1 integrase following selection of R263K with further dolutegravir treatment: a case report from the P1093 study. Abstr 8th IAS Conf HIV Pathog Treatment Prevent. IAS, Geneva, Switzerland.
25. Katlama C, Murphy R. 2012. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 21:523-530. http://dx.doi.org/10.1517/13543784.2012.661713.
26. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
27. Hardy IBB, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, Roger M. 2014. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 70:405-411.
28. Carganico ADS, Ehret R, Berg T, Baumgarten A, Obermeier M, Walter H. 2014. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS 17(4 Suppl 3):19749.
29. Malet I, Thierry E, Wirden M, Lebourgeois S, Subra F, Katlama C, Deprez E, Calvez V, Marcelin AG, Delelis O. 23 July 2015. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother http://dx.doi.org/10 .1093/jac/dkv197.
30. Underwood M, DeAnda F, Dorey D, Hightower K, Wang R, Griffith S, Horton J. 2015. Resistance post week 48 in ART-experienced, integrase inhibitor-naïve subjects with dolutegravir (DTG) versus raltegravir (RAL) in SAILING (ING111762). Abstr 13th Eur HIV Hepat Workshop. Virology Education, Utrecht, The Netherlands.